Copyright
©The Author(s) 2017.
World J Nephrol. Jul 6, 2017; 6(4): 201-208
Published online Jul 6, 2017. doi: 10.5527/wjn.v6.i4.201
Published online Jul 6, 2017. doi: 10.5527/wjn.v6.i4.201
Table 1 Patient characteristics n (%)
Two clearance studies | Three clearance studies | Four clearance studies | |
Patient number | 166 | 84 | 44 |
Age at onset of peritoneal dialysis, yr | 52 ± 15 | 51 ± 16 | 51 ± 18 |
Male | 94 (56.6) | 46 (54.8) | 26 (59.1) |
Female | 72 (43.4) | 38 (45.2) | 18 (40.9) |
Diabetic nephropathy | 73 (44.0) | 36 (42.9) | 17 (38.6) |
Table 2 Creatinine excretion in patients with two studies
Variable | 1st clearance study | 2nd clearance study | P value |
PD duration, mo | 9.2 ± 15.2 | 17.4 ± 15.8 | |
VU, L/24-h | 0.54 ± 0.63 | 0.40 ± 0.53 | < 0.001 |
VD, L/24-h | 11.3 ± 3.2 | 12.1 ± 3.6 | NS |
Kt/V urea, weekly | 2.30 ± 0.62 | 2.12 ± 0.03 | 0.003 |
CCr, L/1.73 m2, weekly | 77.9 ± 32.1 | 67.9 ± 18.2 | 0.002 |
SUN, mg/dL | 49.7 ± 15.1 | 49.4 ± 16.2 | NS |
[Cr]S, mg/dL | 9.1 ± 3.3 | 10.1 ± 3.4 | 0.001 |
EXCr U, mg/24-h | 406 ± 337 | 286 ± 350 | 0.003 |
EXCr D, mg/24-h | 680 ± 337 | 769 ± 390 | < 0.001 |
EXCr T, mg/24-h | 1087 ± 470 | 1055 ± 421 | NS |
Table 3 Creatinine excretion in patients with three studies
Variable | 1st clearance study | 2nd clearance study | 3rd clearance study | P value |
PD duration, mo | 8.6 ± 7.8 | 16.8 ± 11.6 | 24.7 ± 16.3 | |
VU, L/24-h | 0.58 ± 0.66 | 0.45 ± 0.59 | 0.38 ± 0.50 | 0.0001 |
VD, L/24-h | 11.5 ± 4.0 | 11.8 ± 3.7 | 12.4 ± 3.7 | NS |
Kt/V urea, weekly | 2.28 ± 0.65 | 2.14 ± 0.58 | 2.12 ± 0.63 | 0.0245 |
CCr, L/1.73 m2, weekly | 79.3 ± 35.6 | 71.4 ± 27.8 | 68.0 ± 26.9 | 0.0335 |
SUN, mg/dL | 50.4 ± 18.5 | 49.5 ± 17.9 | 49.2 ± 19.2 | NS |
[Cr]S, mg/dL | 9.5 ± 3.5 | 9.8 ± 3.4 | 10.1 ± 3.3 | 0.0066 |
EXCr U, mg/24-h | 418 ± 404 | 370 ± 425 | 286 ± 362 | < 0.0001 |
EXCr D, mg/24-h | 731 ± 379 | 767 ± 396 | 779 ± 382 | NS1 |
EXCr T, mg/24-h | 1149 ± 416 | 1137 ± 454 | 1065 ± 442 | 0.0087 |
Table 4 Creatinine excretion in patients with four clearance studies
Variable | 1st clearance study | 2nd clearance study | 3rd clearance study | 4th clearance study | P value |
PD duration, mo | 8.1 ± 12.6 | 16.5 ± 4.4 | 24.5 ± 16.3 | 31.9 ± 16.8 | |
VU, L/24-h | 0.54 ± 0.55 | 0.41 ± 0.49 | 0.33 ± 0.40 | 0.29 ± 0.42 | < 0.0001 |
VD, L/24-h | 11.8 ± 3.9 | 12.2 ± 3.6 | 12.2 ± 3.5 | 12.5 ± 3.2 | NS |
Kt/V urea, weekly | 2.27 ± 0.65 | 2.15 ± 0.56 | 2.13 ± 0.54 | 2.10 ± 0.55 | 0.0356 |
CCr, L/1.73 m2, weekly | 77.5 ± 29.7 | 70.4 ± 28.5 | 68.5 ± 25.7 | 66.1 ± 22.1 | 0.0238 |
SUN, mg/dL | 49.8 ± 16.7 | 49.5 ± 15.4 | 49.2 ± 15.3 | 49.0 ± 13.5 | NS |
[Cr]S, mg/dL | 9.8 ± 3.6 | 10.2 ± 3.7 | 10.8 ± 3.8 | 10.8 ± 3.6 | 0.0009 |
EXCr U, mg/24-h | 411 ± 438 | 382 ± 460 | 272 ± 345 | 282 ± 481 | 0.0011 |
EXCr D, mg/24-h | 755 ± 406 | 788 ± 424 | 808 ± 438 | 853 ± 398 | 0.0021 |
EXCr T, mg/24-h | 1166 ± 440 | 1170 ± 495 | 1080 ± 455 | 1135 ± 521 | NS |
Table 5 Number (percent) of studies with creatinine excretion deviating from baseline by < 15% and ≥ 15%
Study | < 15% from the 1st study | ≥ 15% above the 1st study | ≥ 15% below the 1st study |
Second | 90 (54.2%) | 41 (24.7%) | 35 (21.1%) |
Third | 40 (47.6%) | 28 (33.3%) | 16 (19.1%) |
Fourth | 24 (54.5%) | 11 (25.0%) | 9 (20.5%) |
- Citation: Xu Z, Murata GH, Sun Y, Glew RH, Qualls C, Vigil D, Servilla KS, Golper TA, Tzamaloukas AH. Reproducibility of serial creatinine excretion measurements in peritoneal dialysis. World J Nephrol 2017; 6(4): 201-208
- URL: https://www.wjgnet.com/2220-6124/full/v6/i4/201.htm
- DOI: https://dx.doi.org/10.5527/wjn.v6.i4.201